Patients with desmoid tumors face significant clinical and economic burdens, impacting their quality of life and leading to ...
FOG-001 targets the β-catenin–TCF interaction, a previously "undruggable" target, offering new hope for desmoid tumor treatment. Early clinical trials show FOG-001 leads to significant tumor shrinkage ...
In Naples, today December 5th and tomorrow, the important scientific meeting "Hot Topics on Sarcomas: Precision, Proximity, ...
Experts discuss the complexities of observing desmoid tumors, weighing the benefits of active surveillance against the need ...
Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for people living with cancer, today announced that the U.S. Food and Drug Administration ...
The price target increase reflects Stephens’ strengthened conviction in the longer-term potential of Immunome’s varegacestat treatment for desmoid tumors, which is expected to present top-line data ...
November 2025 saw pivotal FDA approvals, including durvalumab for gastric cancers and pembrolizumab/enfortumab vedotin for ...
TipRanks on MSN
Immunome initiated with a Buy at Truist
Truist analyst Karina Rabayeva initiated coverage of Immunome (IMNM) with a Buy rating and $36 price target The company’s lead asset, ...
RSNA attendees can find Profound at Booth #3153, South Hall A, for demonstrations of the newly launched TULSA-AI Volume Reduction module, along with case studies and feature upgrades from the pilot ...
Profound would also like to congratulate Satoru Takahashi, MD, PhD, of Takatsuki General Hospital in Japan, for receiving a Certificate of Merit award from RSNA for his presentation titled “TULSA for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback